Table 2. Regimens for mantle cell lymphoma (MCL).
This table presents treatment regimens for MCL organized by clinical indication. BR, bendamustine–rituximab; CRR, complete response rate; CrU, unconfirmed complete response rate; LBR, lenalidomide, bendamustine, and rituximab; ORR, overall response rate; NR, not reported; R 2, lenalidomide plus rituximab; R-BAC(500), rituximab, bendamustine, and cytarabine with low-dose cytarabine; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone; R-DHAP, rituximab, dexamethasone, cytarabine, and cisplatin; R-Hyper-CVAD, rituximab plus fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone; RiBVD, rituximab, bendamustine, bortezomib, and dexamethasone; VcR-CVAD, bortezomib, rituximab, hyper-fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone; VR-CAP, bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone.
| Treatment category | Regimen | Number of
patients |
ORR | CRR (CrU) | Reference |
|---|---|---|---|---|---|
| Fit patients | R-Hyper-CVAD | 97 | 97% | 77% (87%) | 12 |
| VcR-CVAD | 75 | 95% | 68% | 11 | |
| R-DHAP x 4 | 299 | 89% | 41% (77%) | 20 | |
| R-DHAP/R-CHOP x 6 | 248 | 94% | 55% (91%) | 13 | |
| Unfit patients | BR | 50 | 94% | 50% | 22 |
| RiBVD | 74 | 86% | NR (74%) | 24 | |
| LBR | 50 | 88% | 32% (64%) | 25 | |
| R 2 | 38 | 92% | 64% | 26 | |
| VR-CAP | 229 | 92% | 53% | 27 | |
| R-BAC(500) | 57 | NR | 91% | 28 | |
| Relapsed disease | Bortezomib | 155 | 33% | 6% (8%) | 29 |
| Temsirolimus | 54 | 22% | 2% | 30 | |
| Lenolidamide | 170 | 78% | 19% (11%) | 31 | |
| Ibrutinib | 139 | 72% | 19% | 8 | |
| Acalabrutinib | 124 | 81% | 40% | 32 | |
| Ibrutinib + Venetoclax | 24 | 71% | 62% | 33 |